Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia.

Mortadah AlsalmanHussain AlkhalifaAli AlkhalifaMustafa AlsubieNora AlMurayhilAbdulaziz AlthafarMohammed AlbarqiAbdulrahman AlnaimAbdul Sattar Khan

Published in: Health science reports (2021)

HU is a long-established and effective disease-modifying agent for SCD patients, but it is underutilized. The causality of underuse is bidirectional between patients and healthcare providers. It is essential to educate healthcare providers and patients with SCD about hydroxyurea role in modifying disease severity, resolving adverse events, and achieving full benefits.

Keyphrases

healthcare
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
emergency department
patient reported outcomes
social media
health information
adverse drug
electronic health record